Table 4.
In-hospital medications
| STEMI (n=514) | UA/NSTEMI (n=520) | |
|---|---|---|
| At least one in-hospital medication | 514 (100.0) | 520 (100.0) |
| Total number of in-hospital | ||
| medications†, median (min–max) | 9.0 (4–15) | 8.0 (3–19) |
| Thrombolytics | ||
| At least one thrombolytic | 68 (13.2) | 0 (0.0) |
| Streptokinase | 6 (1.2) | 0 (0.0) |
| t-PA | 62 (12.1) | 0 (0.0) |
| Total number† | ||
| n* | 68 | |
| Median (min–max) | 1.0 (1.0–1.0) | – |
| Antiplatelets | ||
| At least one antiplatelet | 514 (100.0) | 520 (100.0) |
| Acetylsalicylic acid | 513 (99.8) | 516 (99.2) |
| Ticlopidine | 5 (1.0) | 0 (0.0) |
| Clopidogrel | 505 (98.2) | 471 (90.6) |
| Any GP IIb/IIIa | 103 (20.0) | 32 (6.2) |
| Abciximab | 3 (0.6) | 0 (0.0) |
| Tirofiban | 100 (19.5) | 32 (6.2) |
| Total number† | ||
| n* | 514 | 520 |
| Median (min–max) | 4.0 (1–7) | 3.0 (1–9) |
| Anticoagulants | ||
| At least one anticoagulant | 481 (93.6) | 422 (81.2) |
| Unfractioned heparin | 268 (52.1) | 193 (37.1) |
| Low molecular weight heparin | 317 (61.7) | 284 (54.6) |
| Warfarin/Acenocoumarol | 0 (0.0) | 3 (0.6) |
| Total number† | ||
| n* | 481 | 422 |
| Median (min–max) | 1.0 (1–4) | 1.0 (1–4) |
| Other CV Therapy | ||
| At least one other CV therapy | 513 (99.8) | 518 (99.6) |
| Beta blockers | 459 (89.3) | 475 (91.3) |
| ACE inhibitor/ARB | 436 (84.8) | 449 (86.3) |
| Statins | 496 (96.5) | 498 (95.8) |
| Other anti-lipid agents | 25 (4.9) | 14 (2.7) |
| Aldosterone inhibitors | 29 (5.6) | 25 (4.8) |
| Loop diuretics | 34 (6.6) | 39 (7.5) |
| Other non-loop diuretics | 14 (2.7) | 10 (1.9) |
| Ca-channel blocker | 17 (3.3) | 49 (9.4) |
| Other | 33 (6.4) | 46 (8.8) |
| Total number† | ||
| n* | 513 | 518 |
| Median (min–max) | 3.0 (1–6) | 3.0 (1–7) |
| Other non-CV therapy | ||
| At least one non-CV therapy | 416 (80.9) | 384 (73.8) |
| PPIs | 292 (56.8) | 267 (51.3) |
| Esomeprazole | 87 (16.9) | 115 (22.1) |
| Lansoprazole | 81 (15.8) | 62 (11.9) |
| Omeprazole | 36 (7.0) | 16 (3.1) |
| Pantoprazole | 91 (17.7) | 78 (15.0) |
| Rabeprazole | 2 (0.4) | 0 (0.0) |
| H2-receptor antagonist | ||
| NSAIDs (traditional and coxibs) | ||
| Total number† | ||
| n* | 416 | 384 |
| Median (min–max) | 1.0 (1–2) | 1.0 (1–3) |
ACE - angiotensin-converting-enzyme inhibitor; ARB - angiotensin receptor blockers; Ca - calcium; CV - cardiovascular; NSAIDs - non-steroidal anti-inflammatory drugs; NSTEMI - non-ST-segment elevation myocardial infarction; PPIs - proton pump inhibitors; r - PA-reteplase; SD - standard deviation; STEMI - ST-segment elevation myocardial infarction; TNK-t-PA - tenecteplase; t-PA - tissue-type plasminogen activator; UA-unstable angina
Total number of medication records provided, including multiple dose types or levels for each medication as well as multiple medication types. Number of unique doses recorded. Note- for patients with no in-hospital antiplatelet use recorded, any discharge antiplatelet is assumed to have also been an in-hospital maintenance dose